Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung Cancer (CONVERT)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00433563 |
Recruitment Status :
Completed
First Posted : February 12, 2007
Last Update Posted : September 8, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known which schedule of radiation therapy is more effective when given together with chemotherapy in treating small cell lung cancer.
PURPOSE: This randomized phase III trial is studying two different schedules of radiation therapy to compare how well they work when given together with cisplatin and etoposide in treating patients with limited stage small cell lung cancer.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Lung Cancer | Radiation: Once daily radiotherapy Radiation: Twice daily radiotherapy | Not Applicable |
OBJECTIVES:
Primary
- Compare overall survival of patients with limited stage small cell lung cancer treated with chemoradiotherapy comprising cisplatin, etoposide, and once vs twice daily radiotherapy.
Secondary
- Compare local progression-free survival of patients treated with these regimens.
- Compare metastasis-free survival of patients treated with these regimens.
- Compare the toxicity of these regimens in these patients.
- Compare response rates in patients treated with these regimens.
- Compare the cytotoxic dose intensity of these regimens in these patients.
- Compare the dose intensity of two different schedules of radiotherapy in these patients.
OUTLINE: This is a multicenter, randomized, controlled study. Patients are stratified according to participating center, ECOG performance status (0-1 vs 2), and lactic dehydrogenase, sodium, and alkaline phosphatase levels. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive cisplatin IV over 2 hours on days 1-3 OR on day 1 only and etoposide IV over 45-90 minutes on days 1-3. Treatment repeats every 21 days for up to 6 courses. During course 2, patients undergo concurrent radiotherapy once daily 5 days a week for 6½ weeks (total of 33 fractions).
- Arm II: Patients receive cisplatin and etoposide as in arm I. During courses 2 and 3, patients undergo concurrent radiotherapy twice daily 5 days a week for 3 weeks (total of 30 fractions).
In both arms, treatment continues in the absence of disease progression or unacceptable toxicity.
Beginning 3-4 weeks after completion of chemoradiotherapy, patients in both arms achieving a complete or partial response with no evidence of brain metastasis undergo prophylactic cranial irradiation once daily 5 days a week for 2 weeks (total of 10 fractions).
After completion of study treatment, patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 532 patients will be accrued for this study.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 547 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A 2-Arm Randomized Controlled Trial of Concurrent Chemo-Radiotherapy Comparing Twice-Daily and Once-Daily Radiotherapy Schedules in Patients With Limited Stage Small Cell Lung Cancer (SCLC) and Good Performance Status [CONVERT] |
Study Start Date : | April 2008 |
Actual Primary Completion Date : | February 2016 |
Actual Study Completion Date : | January 2019 |
Arm | Intervention/treatment |
---|---|
Experimental: Once daily radiotherapy
Once daily radiotherapy
|
Radiation: Once daily radiotherapy
Standard of care chemotherapy (cisplatin/etoposide) + once daily radiotherapy Radiation: Twice daily radiotherapy Standard of care chemotherapy (cisplatin/etoposide) + twice daily radiotherapy |
Active Comparator: Twice daily radiotherapy
Twice daily radiotherapy
|
Radiation: Once daily radiotherapy
Standard of care chemotherapy (cisplatin/etoposide) + once daily radiotherapy Radiation: Twice daily radiotherapy Standard of care chemotherapy (cisplatin/etoposide) + twice daily radiotherapy |
- Overall survival [ Time Frame: August 2015 ]
- Local progression-free survival [ Time Frame: August 2015 ]
- Metastasis-free survival [ Time Frame: August 2015 ]
- Toxicity of treatment [ Time Frame: August 2015 ]
- Cytotoxic dose intensity [ Time Frame: August 2015 ]
- Radiotherapy dose intensity [ Time Frame: August 2015 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion/exclusion criteria:
- Either sex, age ≥18 years
- Performance status ECOG grade 0-1. Patients with PS 2 whose general condition is explained by obstructive/bulky disease likely to improve after the first cycle of chemotherapy can be included at the discretion of the local investigator. Patients with PS 2 as a result of comorbid conditions will be excluded.
- Histologically or cytologically confirmed SCLC
- No patients with mixed small-cell and non-small-cell histologic features
- No history of previous malignancy in the last 5 years (except non melanomatous skin or in-situ cervix carcinoma). Patients with previous malignancies (except breast cancer) and in remission for at least 5 years can be included.
- Limited stage disease (Veterans Administration Lung Cancer Study Group) ie patients whose disease can be encompassed within a radical radiation portal.
- No pleural or pericardial effusions proven to be malignant
- RT target volume acceptable by the local radiotherapist
-
Pulmonary function
- FEV1 >1 litre or 40% predicted value
- KCO (DLCO/VA) >40%predicted
-
Maximum of one of the following adverse biochemical factors:
- Serum alkaline phosphatase more than >1.5 times the upper limit of normal (ULN)
- Serum sodium < Lower limit of Normal
- Serum LDH > ULN
- Normal serum creatinine and calculated creatinine clearance >50 ml/min. If calculated creatinine clearance is <50 ml/mn according to the Cockroft and Gault formula, an EDTA clearance should be performed
-
Adequate haematological function
- Neutrophils >1.5 x 109/l
- Platelets >100 x 109/l
- Adequate liver function: ALT & AST <= 2.5 x ULN
- No other previous or concomitant illness or treatment which in the opinion of the clinician will interfere with the trial treatments or comparisons
- No prior surgical resection of the primary tumour, no prior radiotherapy for lung cancer
- Considered fit to receive any of the trial regimens
- Female patients must satisfy the investigator that they are not pregnant, or are not of child-bearing potential, or are using adequate contraception. Men must also use adequate contraception, as etoposide is clastogenic.
- Patients must not be breastfeeding
- Patient has read the patient information sheet and has signed the consent form.
- Patients available for follow-up
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00433563
United Kingdom | |
The Christie NHS Foundation Trust | |
Manchester, United Kingdom, M20 4BX |
Study Chair: | Corinne Faivre-Finn, MD | The Christie NHS Foundation Trust |
Responsible Party: | The Christie NHS Foundation Trust |
ClinicalTrials.gov Identifier: | NCT00433563 |
Other Study ID Numbers: |
CDR0000531709 CHNT-CONVERT ( Other Identifier: Christie Hospital NHS Foundation Trust ) CHNT-CTAAC-CONVERT-C17052/A815 ( Other Grant/Funding Number: Cancer Research UK ) |
First Posted: | February 12, 2007 Key Record Dates |
Last Update Posted: | September 8, 2022 |
Last Verified: | September 2022 |
limited stage small cell lung cancer |
Lung Neoplasms Small Cell Lung Carcinoma Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms |